Cardiac complications of chemotherapy: Role of biomarkers

Current Treatment Options in Cardiovascular Medicine

Volumn 16, Issue 6, 2014, Pages

  Colombo, Alessandro ^a   Sandri, Maria T ^a   Salvatici, Michela ^a   Cipolla, Carlo M ^a   Cardinale, Daniela ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

ACEI; Beta blockers; Biomarkers; Cancer therapy; Cardiotoxicity; Heart failure; Left ventricular dysfunction; Natriuretic peptides; Prevention; Treatment; Troponin

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ASCORBIC ACID; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; CARNITINE; CARVEDILOL; ENALAPRIL; ERYTHROPOIETIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROBUCOL; RAZOXANE; REACTIVE OXYGEN METABOLITE; TROPONIN; UBIDECARENONE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG MONITORING; FOLLOW UP; FUNCTIONAL STATUS; HEART ARRHYTHMIA; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HUMAN; LUNG EDEMA; PROGNOSIS; PROPHYLAXIS; SUDDEN CARDIAC DEATH; TREATMENT OUTCOME;

EID: 84901288595     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-014-0313-6     Document Type: Article

References (75)

1. Hunt SA, Abraham WT, Chin MH, et al. Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53:e1-e90.
2. Eschenhagen T, Force T, Ewer MS, et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2011;13(1):1-10.
3. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol. 2002;13 (5):699-709. (Pubitemid 34567375)
4. Bird BR, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res. 2008;14(1):14-24. (Pubitemid 351377973)
5. Altena R, Perik PJ, van Veldhuisen DJ, et al. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol. 2009;10:391-9.
6. The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined: a consensus document of the Joint European Society of Cardiology/American College of Cardiology for the redefinition of myocardial infarction. Eur Heart J. 2000;21(18):1502-13.
7. Newby LK, Jesse RL, Babb JD, et al. ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2012;60(23):2427-63.
8. O'Brien PJ. Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity. Toxicology. 2008;245(3):206-18.
9. Lipshultz SE, Rifai N, Sallan SE, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation. 1997;96(8):2641-8. (Pubitemid 27451357)
10. Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010;11(10):950-61.
11. Lipshultz SE, Miller TL, Scully RE, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol. 2012;30(10):1042-9.
12. Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol. 2000;36(2):517-22.
13. Morandi P, Ruffini PA, Benvenuto GM, et al. Serum cardiac troponin I levels and ECG/Echo monitoring in breast cancer patients undergoing high-dose (7 g/m2) cyclophosphamide. Bone Marrow Transplant. 2001;28(3):277-82. (Pubitemid 32780881)
14. Cardinale D, Sandri MT, Martinoni A, et al. Myocardial injury revealed by plasma troponina I in breast cancer treated with high-dose chemotherapy. Ann Oncol. 2002;13(5):710-5. (Pubitemid 34567376)
15. Auner HW, Tinchon C, Brezinschek RI, et al. Monitoring of cardiac function by serum cardiac troponin T levels, ventricular repolarisation indices, and echocardiography after conditioning with fractionated total body irradiation and high-dose cyclophosphamide. Eur J Haematol. 2002;69(1):1-6. (Pubitemid 35155433)
16. Sandri MT, Cardinale D, Zorzino L, et al. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem. 2003;49(2):248-52. (Pubitemid 36143446)
17. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109(22):2749-54. (Pubitemid 38737923)
18. Specchia G, Buquicchio C, Pansini N, et al. Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines. J Lab Clin Med. 2005;145(4):212-20. (Pubitemid 40692404)
19. Kilickap S, Barista I, Akgul E, et al. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol. 2005;16(5):798-804. (Pubitemid 40767103)
20. Dodos F, Halbsguth T, Erdmann E, et al. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol. 2008;97(5):318-26. (Pubitemid 351725058)
21. Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28(25):3910-6.
22. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26(32):5204-12.
23. Morris PG, Chen C, Steingart R, et al. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin Cancer Res. 2011;17(10):3490-9.
24. .• Sawaya H, Sebag IA, Plana JC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5(5):596-603. This study suggests the possibility that combining biomarkers with the newest echocardiographic techniques may have a greater value in the prediction of cardiotoxicity.
25. Ewer MS, Ewer SM. Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction. J Clin Oncol. 2010;28(25):3901-4.
26. Adamcová M, Simunek T, Kaiserová H, et al. In vitro and in vivo examination of cardiac troponins as biochemical markers of drug induced cardiotoxicity. Toxicology. 2007;237(1-3):218-28. (Pubitemid 47031418)
27. Cardinale D, Sandri MT. Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis. 2010;53(2):121 -9.
28. .• Lenihan DJ, Oliva S, Chow EJ, Cardinale D. Cardiac toxicity in cancer survivors. Cancer. 2013;119 Suppl 11:2131-42. Overview of current perspectives about identification, treatment, or prevention of cardiac complications resulting from cancer therapy.
29. Dolci A, Dominici R, Cardinale D, et al. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. Am J Clin Pathol. 2008;130(5):688-95.
30. .• Gerszten RE, Asnani A, Carr SA. Status and prospects for discovery and verification of new biomarkers of cardiovascular disease by proteomics. Circ Res. 2011;109:463-74. An overview of emerging techniques aimed at the discovery and validation of new cardiovascular biomarkers.
31. Kimura K, Yamaguchi Y, Horii M, Kawata H, Yamamoto H, Uemura S, et al. ANP is cleared much faster than BNP in patients with congestive heart failure. Eur J Clin Pharmacol. 2007;63(7):699-702. (Pubitemid 46911345)
32. Chowdhury P, Kehl D, Choudhary R, Maisel A. The use of biomarkers in the patient with heart failure. Curr Cardiol Rep. 2013;15(6):372.
33. Suzuki T, Hayashi D, Yamazaki T, et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J. 1998;136(2):362-3. (Pubitemid 28368863)
34. Horacek JM, Pudil R, Jebavy L, et al. Assessment of anthracycline-induced cardiotoxicity with biochemical markers. Exp Oncol. 2007;29(4):309-13. (Pubitemid 351236322)
35. Nousiainen T, Jantunen E, Vanninen E, et al. Acute neurohumoral and cardiovascular effects of idarubicin in leukemia patients. Eur J Haematol. 1998;61(5):347-53. (Pubitemid 28551685)
36. Hayakawa H, Komada Y, Hirayama M, et al. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol. 2001;37(1):4-9. (Pubitemid 32613628)
37. Meinardi MT, Van Veldhuisen DJ, Gietema JA, et al. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol. 2001;19(10):2746-53. (Pubitemid 32441381)
38. Nousiainen T, Vanninen E, Jantunen E, et al. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med. 2002;251(3):228-34. (Pubitemid 34227187)
39. Daugaard G, Lassen U, Bie P, et al. Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail. 2005;7(1):87-93. (Pubitemid 40092497)
40. Sandri MT, Salvatici M, Cardinale D, et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem. 2005;51(11):1405-10. (Pubitemid 41060872)
41. Pinarli FG, Oǧuz A, Tunaoǧlu FS. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy. Pediatr Blood Cancer. 2005;44(4):370-7. (Pubitemid 40316030)
42. Nakamae H, Tsumura K, Terada Y, et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer. 2005;104(11):2492-8. (Pubitemid 41691573)
43. Pichon MF, Cvitkovic F, Hacene K, et al. Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography. In Vivo. 2005;19(3):567-76. (Pubitemid 40568136)
44. Soker M, Kervancioglu M. Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy. Saudi Med J. 2005;26(8):1197-202. (Pubitemid 41288627)
45. Erkus B, Demirtas S, Yarpuzlu AA, et al. Early prediction of anthracycline induced cardiotoxicity. Acta Paediatr. 2007;96(4):506-9. (Pubitemid 46466109)
46. Aggarwal S, Pettersen MD, Bhambhani K, et al. B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children. Pediatr Blood Cancer. 2007;49(6):812-6. (Pubitemid 47519518)
47. Ekstein S, Nir A, Rein AJ, et al. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children. J Pediatr Hematol Oncol. 2007;29(7):440-4. (Pubitemid 47026244)
48. Zver S, Zadnik V, Bunc M, et al. Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation. Int J Hematol. 2008;85(5):408-14.
49. Knobloch K, Tepe J, Lichtinghagen R, et al. Simultaneous hemodynamic and serological cardiotoxicity monitoring during immunotherapy with trastuzumab. Int J Cardiol. 2008;125(1):113-5. (Pubitemid 351305407)
50. Broeyer FJ, Osanto S, Ritsema van Eck HJ, et al. Evaluation of biomarkers for cardiotoxicity of anthracycline-based chemotherapy. J Cancer Res Clin Oncol. 2008;134(9):961-8.
51. Mavinkurve-Groothuis AM, Groot-Loonen J, Bellersen L, et al. Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines. Pediatr Blood Cancer. 2009;52(5):631-6.
52. Cil T, Kaplan AM, Altintas A, et al. Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series. Clin Drug Investig. 2009;29(2):131-7.
53. Roziakova L, Bojtarova E, Mistrik M, et al. Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation. J Exp Clin Cancer Res. 2012;31:13.
54. Romano S, Fratini S, Ricevuto E, et al. Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients. Br J Cancer. 2011;105(11):1663-8.
55. Lee HS, Son CB, Shin SH, et al. Clinical correlation between brain natriutetic peptide and anthracyclin-induced cardiac toxicity. Cancer Res Treat. 2008;40(3):121-6.
56. Feola M, Garrone O, Occelli M, et al. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. Int J Cardiol. 2011;148(2):194-8.
57. Wouters KA, Kremer LC, Miller TL, et al. Protecting against anthracyclines-induced myocardial damage: a review of the most promising strategies. Br J Haematol. 2005;131:561-78. (Pubitemid 43899624)
58. Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114(23):2474-81. (Pubitemid 44901520)
59. Geisberg CA, Sawyer DB. Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage. Curr Hypertens Rep. 2010;12:404-10.
60. Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin treated children with acute lymphoblastic leukemia. N Engl J Med. 2004;351(2):145-53. (Pubitemid 38886649)
61. van Dalen EC, Caron HN, Dickinson HO, et al. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2011;(6):15-17.
62. Huh WW, Jaffe N, Durand JB, et al. Comparison of doxorubicin cardiotoxicity in pediatric sarcoma patients when given with dexrazoxane versus as continuous infusion. Pediatr Hematol Oncol. 2010;27(7):546-57.
63. FDA statement on Dexrazoxane. www.fda.gov/Drugs/DrugSafety/ucm263729.htm. Last Accessed 3 Sep 2013.
64. Tebbi CK, London WB, Friedman D, et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol. 2007;25(5):493-500. (Pubitemid 350002954)
65. Barry EV, Vrooman LM, Dahlberg SE, et al. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol. 2008;26(7):1106-11.
66. Spallarossa P, Garibaldi S, Altieri P, et al. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol. 2004;37(4):837-46. (Pubitemid 39222076)
67. Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006;48(11):2258-62. (Pubitemid 44855419)
68. Kaya MG, Ozkan M, Gunebakmaz O, et al. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol. 2013;167(5):2306-10.
69. Bosch X, Esteve J, Sitges M, et al. Prevention of chemotherapy-induced left ventricular dysfunction with enalapril and carvedilol: rationale and design of the OVERCOME trial. J Card Fail. 2011;17:643-8.
70. Barry E, Alvarez JA, Scully RE, et al. Anthracycline induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother. 2007;8(8):1039-58.
71. Albini A, Pennesi G, Donatelli F, et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102(1):14-25.
72. Cadeddu C, Piras A, Mantovani G, et al. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J. 2010;160(3):487.e1-7.
73. Dessì M, Madeddu C, Piras A, et al. Long-term, up to 18 months, protective effects of the angiotensin II receptor blocker telmisartan on Epirubin-induced inflammation and oxidative stress assessed by serial strain rate. Springerplus. 2013;2(1):198.
74. Ederhy S, Massard C, Dufaitre G, et al. Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in Phase 1 trials. Investig New Drugs. 2010;30(2):611-5.
75. Curigliano G, Cardinale D, Suter T, ESMO Guidelines Working Group, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23(7):vii155- 66.